Regulatory and valuation challenges of immune checkpoint inhibitors in lung cancer

Research output: Types of ThesisDoctoral ThesisInternal

167 Downloads (Pure)

Abstract

Advances in innovative drug development translated into tangible improvements in clinical outcomes for patients with non-small cell lung cancer (NSCLC). Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has transformed the standard of care for NSCLC patients. Although ICIs have brought meaningful opportunities in NSCLC care and transformed the treatment landscape, their regulatory decisions and economic value assessments pose important challenges. In this research, regulatory and valuation challenges of ICIs in NSCLC were explored to help support the future use of ICIs in health systems.
Original languageEnglish
Awarding Institution
  • Erasmus University Rotterdam
Supervisors/Advisors
  • de Groot, Carin, Supervisor
  • Redekop, Ken, Co-supervisor
Award date7 Sept 2023
Place of PublicationRotterdam
Print ISBNs978-94-6361-871-7
Publication statusPublished - 7 Sept 2023

Fingerprint

Dive into the research topics of 'Regulatory and valuation challenges of immune checkpoint inhibitors in lung cancer'. Together they form a unique fingerprint.

Cite this